Join us on Thursday, July 6^th for this NCPD-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Thursday, July 6, 2023
5:00 PM – 6:00 PM Eastern Time
Live NCPD-accredited webinar

A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the importance of clinical presentation, biomarker profile, coexisting medical conditions and psychosocial status in the selection of systemic therapy for patients with newly diagnosed CLL.
• Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton’s tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for CLL, and use this information to counsel patients regarding available front-line options.
• Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and explain the potential risks and benefits of time-limited therapy to individuals with the disease.
• Appraise available Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors and consider the implications of these findings for clinical decision making for patients with newly diagnosed or previously treated CLL.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy in patients with newly diagnosed CLL.
• Analyze how age, performance status, prior therapeutic exposure and other biologic and disease related factors impact the selection and sequencing of therapy for patients with relapsed/refractory (R/R) CLL in order to provide education regarding appropriate treatment considerations.
• Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies employed in the management of CLL.
• Recall available and emerging data with novel agents and combination strategies currently under investigation in CLL and, where applicable, discuss clinical trial participation with eligible patients.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.